Nacubactam

Summary

Nacubactam (CHEMBL3989959) is a phase-3 clinical-stage small molecule; indicated across 3 conditions including urinary tract infection and kidney disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 3 conditions
• Clinical trials: 6
• Chemistry: 324.31 Da · C9H16N4O7S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3989959
Name	Nacubactam
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	73386748
Molecular formula	C9H16N4O7S
Molecular weight	324.31
InChIKey	RSBPYSTVZQAADE-RQJHMYQMSA-N

SMILES: C1C[C@H](N2C[C@@H]1N(C2=O)OS(=O)(=O)O)C(=O)NOCCN

IUPAC name: [(2S,5R)-2-(2-aminoethoxycarbamoyl)-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate

Also known as: FPI-1459, Nacubactam, RG-6080, RG6080, RO-7079901, RO7079901, NACUBACTAM

Patent coverage: 48 distinct patent families (150 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Beta-lactamase, Beta-lactamase OXA-23, Beta-lactamase OXA-1, Carbapenem-hydrolyzing beta-lactamase KPC.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P05364	6.07	IC50	845	nM	CHEMBL_ACT_25498503
Q9F663	6.06	IC50	869	nM	CHEMBL_ACT_25498501
P13661	5.52	IC50	3050	nM	CHEMBL_ACT_25498505

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
urinary tract infection	1	MONDO:0100338	EFO:0003103
kidney disorder	1	MONDO:0005240	EFO:0003086
gram-negative bacterial infections	1	MONDO:0021678	MONDO:0021678

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE1	4
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05887908	PHASE3	COMPLETED	Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis
NCT05905055	PHASE3	COMPLETED	P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales
NCT02972255	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7079901 and the Combination of RO7079901 With Meropenem in Adult Healthy Volunteers
NCT02975388	PHASE1	COMPLETED	A Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics (PK) of RO7079901
NCT03174795	PHASE1	COMPLETED	A Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Participants With a Complicated Urinary Tract Infection
NCT03182504	PHASE1	COMPLETED	A Study to Investigate the Intrapulmonary Lung Penetration of Nacubactam in Healthy Participants

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).